Highlights Anavex Life Sciences Corp.

Equities

AVXL

US0327973006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3.65 ^USD	+6.10%		-0.82%	-60.79%

Mar. 18	Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia	CI
Feb. 07	Transcript : Anavex Life Sciences Corp., Q1 2024 Earnings Call, Feb 07, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia	Mar. 18	CI
Anavex Life Sciences Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07	CI
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia	Jan. 16	CI
Anavex Life Sciences Corp. Provides an Update on Rett Syndrome Program	Jan. 02	CI
Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome	Dec. 20	CI
Anavex Life Sciences Shares Rise on European Approval of Marketing Application for Oral Blarcamesine in Alzheimer's	Dec. 19	MT
Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease	Dec. 19	CI
Anavex Life Sciences Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 27	CI
Anavex Life Sciences Corp. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Nov. 27	CI
Anavex Life Sciences Begins European Marketing Authorization Process for Blarcamesine to Treat Alzheimer's Disease	Nov. 20	MT
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer?s Disease to European Medicines Agency	Nov. 20	CI
Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease	23-10-25	CI
Anavex Life Sciences Corp. Announces Phase 2b/3 Trial of Blarcamesine (ANAVEX 2-73) in Patients with Alzheimer?s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration	23-09-14	CI
Anavex Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-08	CI
Anavex Life Sciences Reports Publication of ANAVEX®?3-71 in Clinical Journal Confirming ANAVEX®? 3-71 Clinical Cardiovascular Safety	23-08-07	CI
Anavex Life Sciences Corp. Announces Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX(R)2-73 (blarcamesine) for Rett Syndrome	23-06-28	CI
Anavex Life Sciences, Partex to Use Artificial Intelligence for Drug Development	23-06-27	MT
Anavex Life Sciences Corp. and Partex N.V. Group Announce Strategic Partnership to Leverage AI for Drug Development	23-06-27	CI
Anavex Life Sciences Corp.'s ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome	23-06-15	CI
Anavex Life Sciences Corp. Announces Completion of Anavex((R))2-73 (Blarcamesine) Excellence Phase 2/3 Rett Syndrome Clinical Trial	23-06-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Anavex Life Sciences Corp.

Equities

AVXL

US0327973006

Highlights

Filters